0000899243-22-031922.txt : 20220923 0000899243-22-031922.hdr.sgml : 20220923 20220923180017 ACCESSION NUMBER: 0000899243-22-031922 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201116 FILED AS OF DATE: 20220923 DATE AS OF CHANGE: 20220923 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: KILTS JAMES M CENTRAL INDEX KEY: 0001025094 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-39695 FILM NUMBER: 221263202 MAIL ADDRESS: STREET 2: 120 PARK AVE CITY: NEW YORK STATE: NY ZIP: 10017 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Viatris Inc CENTRAL INDEX KEY: 0001792044 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 834364296 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1000 MYLAN BOULEVARD CITY: CANONSBURG STATE: PA ZIP: 15317 BUSINESS PHONE: (724) 514-1465 MAIL ADDRESS: STREET 1: 1000 MYLAN BOULEVARD CITY: CANONSBURG STATE: PA ZIP: 15317 FORMER COMPANY: FORMER CONFORMED NAME: Upjohn Inc DATE OF NAME CHANGE: 20191023 4/A 1 doc4a.xml FORM 4/A SUBMISSION X0306 4/A 2020-11-16 2020-11-18 0 0001792044 Viatris Inc VTRS 0001025094 KILTS JAMES M 1000 MYLAN BOULEVARD CANONSBURG PA 15317 1 0 0 0 Common Stock 2020-11-16 4 A 0 35764 A 36044 D On November 16, 2020, Mylan N.V. ("Mylan") completed the transaction pursuant to which Mylan combined with Pfizer Inc.'s ("Pfizer") Upjohn business (the "Upjohn Business") in a Reverse Morris Trust transaction (the "Combination") and Upjohn Inc. ("Upjohn") became the parent entity of the combined Upjohn Business and Mylan business and was renamed "Viatris Inc." ("Viatris"). Pursuant to the terms of the Business Combination Agreement (as amended), dated July 29, 2019, by and among Mylan, Pfizer, Upjohn and certain other affiliated entities, Upjohn and Mylan effected the Combination through a series of transactions, including that each holder of Mylan ordinary shares received one share of Viatris common stock for each Mylan ordinary share held by such holder (subject to any required withholding tax). Represents shares of Viatris common stock acquired in connection with the Combination on a one-for-one basis in exchange for ordinary shares of Mylan. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share. Includes 280 shares of common stock acquired in the distribution on November 16, 2020 by Pfizer to its stockholders of all of the issued and outstanding shares of Upjohn common stock held by Pfizer by way of pro rata dividend. This filing amends a prior form filed on November 18, 2020 and does not represent any new transaction. The November 18, 2020 Form 4 filing incorrectly stated that 36,889 shares of Viatris common stock had been acquired in connection with the Combination on a one-for-one basis in exchange for ordinary shares of Mylan; the actual number of shares was 35,764 as shown in the amended line item above. This amendment shall also serve to correct the corresponding amounts that were carried forward on Form 4 reports subsequently filed by the reporting person. /s/ Kevin Macikowski, by power of attorney 2022-09-23